Keywords
rectal cancer, preoperative chemoradiotherapy, pathological complete response, pCR, CEA, mrTRG.
Abstract
Objective: To identify factors associated with pathological complete response after long-course preoperative chemoradiotherapy in patients with middle and lower rectal cancer. Subjects and Methods: A retrospective descriptive and analytical study was conducted on 168 patients with stage II–III middle and lower rectal cancer who underwent long-course preoperative chemoradiotherapy followed by radical surgery. Pathological complete response was defined as the absence of viable tumor cells in the primary tumor bed in the surgical specimen, corresponding to Mandard TRG 1/ypT0. Clinical, laboratory, and imaging-related factors were analyzed using univariate tests and multivariable logistic regression.
Results: The pathological complete response rate was 22.0% (37/168). Patients with pathological complete response had a significantly smaller pretreatment tumor size than those without pathological complete response (4.78 ± 1.90 cm vs. 5.81 ± 2.25 cm; p = 0.006) and lower pretreatment CEA levels [2.37 (1.15–3.28) vs. 4.57 (2.55–7.94) ng/mL; p < 0.001]. In multivariable analysis, pretreatment CEA >5 ng/mL was an independent unfavorable factor for pathological complete response (OR = 0.33; 95%CI: 0.14–0.81; p = 0.015). After chemoradiotherapy, mrTRG 1–2 was strongly associated with pathological complete response.
Conclusion: Low pretreatment CEA, smaller baseline tumor size, and post-treatment mrTRG 1–2 were suggestive factors associated with a higher probability of pathological complete response after long-course preoperative chemoradiotherapy.
References
[1]
Benson AB, Venook AP, Al-Hawary MM, et al. Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(10):1139-1167. doi:10.6004/jnccn.2022.0051.
Google Scholar
[2]
Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-1740. doi:10.1056/NEJMoa040694.
Google Scholar
[3]
Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620-4625. doi:10.1200/JCO.2006.06.7629.
Google Scholar
[4]
Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-1123. doi:10.1056/NEJMoa060829.
Google Scholar
[5]
Maas M, Nelemans PJ, Valentini V, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11(9):835-844. doi:10.1016/S1470-2045(10)70172-8.
Google Scholar
[6]
Rödel C, Martus P, Papadoupolos T, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(34):8688-8696. doi:10.1200/JCO.2005.02.1329.
Google Scholar
[7]
Al-Sukhni E, Attwood K, Mattson DM, Gabriel E, Nurkin SJ. Predictors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer. Ann Surg Oncol. 2016;23(4):1177-1186. doi:10.1245/s10434-015-5017-y.
Google Scholar
[8]
Choi E, Kim JH, Kim OB, et al. Predictors of pathologic complete response after preoperative concurrent chemoradiotherapy of rectal cancer. Ann Surg Treat Res. 2016;90(3):163-169. doi:10.4174/astr.2016.90.3.163.
Google Scholar
[9]
Petrelli F, Sgroi G, Sarti E, et al. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg. 2016;263(3):458-464. doi:10.1097/SLA.0000000000000368.
Google Scholar